WO2004005920A3 - Verfahren zur anreicherung und zum nachweis von pathologisch veränderten prion-proteinen (prpsc) - Google Patents

Verfahren zur anreicherung und zum nachweis von pathologisch veränderten prion-proteinen (prpsc) Download PDF

Info

Publication number
WO2004005920A3
WO2004005920A3 PCT/DE2003/002249 DE0302249W WO2004005920A3 WO 2004005920 A3 WO2004005920 A3 WO 2004005920A3 DE 0302249 W DE0302249 W DE 0302249W WO 2004005920 A3 WO2004005920 A3 WO 2004005920A3
Authority
WO
WIPO (PCT)
Prior art keywords
prpsc
pathologic
enriching
tracking
proteins
Prior art date
Application number
PCT/DE2003/002249
Other languages
English (en)
French (fr)
Other versions
WO2004005920A2 (de
Inventor
Claudia Engemann
Katja Hoeschler
Joerg Lehmann
Joerg Gabert
Ulrike Krummrei
Original Assignee
Priontype Gmbh
Schleussner Cathrin
Claudia Engemann
Katja Hoeschler
Joerg Lehmann
Joerg Gabert
Ulrike Krummrei
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Priontype Gmbh, Schleussner Cathrin, Claudia Engemann, Katja Hoeschler, Joerg Lehmann, Joerg Gabert, Ulrike Krummrei filed Critical Priontype Gmbh
Priority to CA002489151A priority Critical patent/CA2489151A1/en
Priority to EA200500125A priority patent/EA200500125A1/ru
Priority to AU2003250773A priority patent/AU2003250773A1/en
Priority to DE10393421T priority patent/DE10393421D2/de
Priority to BR0312282-4A priority patent/BR0312282A/pt
Priority to JP2004518441A priority patent/JP2005531775A/ja
Priority to EP03762453A priority patent/EP1520178A2/de
Priority to US10/520,386 priority patent/US20060094071A1/en
Publication of WO2004005920A2 publication Critical patent/WO2004005920A2/de
Publication of WO2004005920A3 publication Critical patent/WO2004005920A3/de
Priority to NO20050599A priority patent/NO20050599L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/968—Plasmin, i.e. fibrinolysin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

Die vorliegende Erfindung betrifft Verfahren zum Nachweis von pathologisch veränderten Prion-Proteinen (PrPSc) von lebenden Organismen.
PCT/DE2003/002249 2002-07-04 2003-07-04 Verfahren zur anreicherung und zum nachweis von pathologisch veränderten prion-proteinen (prpsc) WO2004005920A2 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002489151A CA2489151A1 (en) 2002-07-04 2003-07-04 Method for enriching and tracking pathologic modified prions-proteins (prpsc)
EA200500125A EA200500125A1 (ru) 2002-07-04 2003-07-04 СПОСОБ ОБОГАЩЕНИЯ И ОБНАРУЖЕНИЯ ПАТОЛОГИЧЕСКИ ИЗМЕНЕННЫХ ПРИОНПРОТЕИНОВ (PrP)
AU2003250773A AU2003250773A1 (en) 2002-07-04 2003-07-04 Method for enriching and tracking pathologic modified prions-proteins (PrPsc)
DE10393421T DE10393421D2 (de) 2002-07-04 2003-07-04 Verfahren zur Anreicherung und zum Nachweis von pathologisch veränderten Prion-Proteinen (PRPSC)
BR0312282-4A BR0312282A (pt) 2002-07-04 2003-07-04 Processo para o enriquecimento e detecção de proteìnas de priÈnios patologicamente modificadas (prpsc)
JP2004518441A JP2005531775A (ja) 2002-07-04 2003-07-04 病理学的に変化したプリオンタンパク質（ＰｒＰＳｃ）の濃縮方法および検出方法
EP03762453A EP1520178A2 (de) 2002-07-04 2003-07-04 Verfahren zur anreicherung und zum nachweis von pathologisch veränderten prion-proteinen (prpsc)
US10/520,386 US20060094071A1 (en) 2002-07-04 2003-07-04 Method for enriching and tracking pathologic modified prions-proteins(prpsc)
NO20050599A NO20050599L (no) 2002-07-04 2005-02-03 Fremgangsmate for a anrike og spore patologisk modifiserte prion-proteiner (PRPsc)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10230141.7 2002-07-04
DE10230141A DE10230141B4 (de) 2002-07-04 2002-07-04 Verfahren und Kit zur Anreicherung und zum Nachweis von veränderten Prion-Proteinen (PrPSc)

Publications (2)

Publication Number Publication Date
WO2004005920A2 WO2004005920A2 (de) 2004-01-15
WO2004005920A3 true WO2004005920A3 (de) 2004-04-29

Family

ID=30009806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2003/002249 WO2004005920A2 (de) 2002-07-04 2003-07-04 Verfahren zur anreicherung und zum nachweis von pathologisch veränderten prion-proteinen (prpsc)

Country Status (12)

Country Link
US (1) US20060094071A1 (de)
EP (1) EP1520178A2 (de)
JP (1) JP2005531775A (de)
CN (1) CN1666106A (de)
AU (1) AU2003250773A1 (de)
BR (1) BR0312282A (de)
CA (1) CA2489151A1 (de)
DE (2) DE10230141B4 (de)
EA (1) EA200500125A1 (de)
NO (1) NO20050599L (de)
PL (1) PL375358A1 (de)
WO (1) WO2004005920A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072236A1 (en) * 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
CA2535261C (en) 2003-08-13 2015-11-24 Chiron Corporation Prion-specific peptide reagents
MX2007008497A (es) * 2005-01-13 2007-09-14 Novartis Vaccines & Diagnostic Ensayos inmunosorbentes enlazados a enzimas usando reactivos de peptidos especificos de prion.
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
EP1848830A4 (de) * 2005-01-13 2009-05-06 Novartis Vaccines & Diagnostic Isolierung pathogener prione
NZ594844A (en) * 2005-09-09 2013-04-26 Novartis Ag Prion-specific peptoid reagents
JP5164971B2 (ja) * 2006-04-21 2013-03-21 ピープルバイオ，アイ エヌ シー 三次元的相互作用を用いてマルチマー形成ポリペプチドのモノマーからマルチマーを分別検出する方法
AU2007317203B2 (en) * 2006-11-10 2010-12-16 Dimerix Bioscience Pty Ltd Detection system and uses therefor
BRPI0910550A2 (pt) * 2008-04-30 2015-09-29 Novartis Ag ensaio para confôrmeros patogênicos
CN103336124B (zh) * 2012-12-11 2015-07-15 武汉工业学院 一种检测朊病毒蛋白(PrPSC)的方法和试剂盒

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039834A1 (en) * 1995-06-07 1996-12-19 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
WO2000029850A1 (en) * 1998-11-17 2000-05-25 Wallac Oy An immunoassay for the determination of transmissible spongiform encephalopathies in bovine
WO2001007474A1 (en) * 1999-07-28 2001-02-01 Kelvin Stott Peptides containing n-substituted d-amino acids for preventing beta-strand association
WO2001007473A1 (en) * 1999-07-28 2001-02-01 Kelvin Stott Peptides containing n-substituted l-amino acids for preventing beta-strand association
WO2001034631A2 (en) * 1999-11-05 2001-05-17 Axonyx, Inc. PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF
WO2002088748A1 (de) * 2001-04-26 2002-11-07 SEILER, Jürgen Verfahren zur diagnose von übertragbaren spongiformen enzephalopathien

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ246059A (en) * 1991-12-03 1995-08-28 Proteus Molecular Design Synthetic polypeptides with at least one antigenic site of a prion protein, methods of their use and manufacture, antibodies thereto, compositions and kits
WO1997021728A1 (en) * 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US6150172A (en) * 1999-01-08 2000-11-21 The United States Of America As Represented By The Secretary Of Agriculture Method and kit for extracting prion protein
EP1216258A1 (de) * 1999-09-28 2002-06-26 Universität Zürich Faktoren mit prionen bindender aktivität im serum und plasma sowie mittel zur bestimmung von übertragbaren spongiformen encephalopathien
AU2001250406A1 (en) * 2000-06-26 2002-01-08 Universitat Zurich Prion-binding activity in serum and plasma determined as plasminogen and fibrinogen
US20020115717A1 (en) * 2000-07-25 2002-08-22 Francine Gervais Amyloid targeting imaging agents and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039834A1 (en) * 1995-06-07 1996-12-19 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
WO2000029850A1 (en) * 1998-11-17 2000-05-25 Wallac Oy An immunoassay for the determination of transmissible spongiform encephalopathies in bovine
WO2001007474A1 (en) * 1999-07-28 2001-02-01 Kelvin Stott Peptides containing n-substituted d-amino acids for preventing beta-strand association
WO2001007473A1 (en) * 1999-07-28 2001-02-01 Kelvin Stott Peptides containing n-substituted l-amino acids for preventing beta-strand association
WO2001034631A2 (en) * 1999-11-05 2001-05-17 Axonyx, Inc. PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF
WO2002088748A1 (de) * 2001-04-26 2002-11-07 SEILER, Jürgen Verfahren zur diagnose von übertragbaren spongiformen enzephalopathien

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HETENYI C ET AL: "Pentapeptide amides interfere with the aggregation of b-amyloid peptide of alzheimer's disease", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 292, no. 4, 12 April 2002 (2002-04-12), pages 931 - 936, XP002965576, ISSN: 0006-291X *
SIGURDSSON E M ET AL: "IN VIVO REVERSAL OF AMYLOID-BETA LESIONS IN RAT BRAIN", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, NEW YORK, NY, US, vol. 59, no. 1, January 2000 (2000-01-01), pages 11 - 17, XP008012465, ISSN: 0022-3069 *
SOTO C ET AL: "INHIBITION OF ALZHEIMER'S AMYLOIDOSIS BY PEPTIDES THAT PREVENT BETA-SHEET CONFORMATION", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 226, no. 3, 24 September 1996 (1996-09-24), pages 672 - 680, XP002050229, ISSN: 0006-291X *
TJERNBERG L O ET AL: "CONTROLLING AMYLOID BETA-PEPTIDE FIBRIL FORMATION WITH PROTEASE-STABLE LIGANDS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 19, 9 May 1997 (1997-05-09), pages 12601 - 12605, XP002050230, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
JP2005531775A (ja) 2005-10-20
EA200500125A1 (ru) 2005-08-25
EP1520178A2 (de) 2005-04-06
PL375358A1 (en) 2005-11-28
CA2489151A1 (en) 2004-01-15
US20060094071A1 (en) 2006-05-04
DE10393421D2 (de) 2005-06-09
DE10230141A1 (de) 2004-02-05
AU2003250773A1 (en) 2004-01-23
WO2004005920A2 (de) 2004-01-15
DE10230141B4 (de) 2004-07-15
CN1666106A (zh) 2005-09-07
BR0312282A (pt) 2005-04-12
NO20050599L (no) 2005-04-01

Similar Documents

Publication Publication Date Title
AU2003280298A1 (en) Methods for the biological treatment of gas
WO2004005920A3 (de) Verfahren zur anreicherung und zum nachweis von pathologisch veränderten prion-proteinen (prpsc)
AU2003277596A1 (en) Method of deuterization
AU2003215781A1 (en) Method for production of phytoalexins
AU2003240526A1 (en) Non-destructive separation of nanomorphic carbon species
AU2003296096A1 (en) Gas producer
AU2003293895A1 (en) Method for the production of isocyanates
WO2004024077A3 (en) Novel composition and methods for the treatment of psoriasis
AU2003260909A1 (en) Method of enhancing multimedia
AU2003260251A1 (en) Piezoactuator and method for production of the piezoactuator
WO2004048597A3 (en) Composition and method for inhibition of microorganisms
AU2003292680A1 (en) Method of selecting novel immunosuppressant
AU2003293272A1 (en) Method for the production of bioprostheses
AU2003235955A1 (en) Method of gas carburizing
AU2003258622A1 (en) Method for the production of $g(b)-carotinoids
AU2003292209A1 (en) Method for the production of optically active dihydropyrones
AU2003228597A1 (en) ANTIBODIES FOR ENZYMES OF THE Omega-OXIDATION PATHWAY AND METHODS RELATING THERETO
WO2004028447A3 (en) Novel compositions and methods for the treatment of psoriasis
AU2003267541A1 (en) Method for the production of substituted trifluoroethylenes
WO2003099783A3 (en) Tropane compounds
EP1599578A4 (de) Verfahren zur verhinderung der gluconoylierung von proteinen
WO2004044170A3 (en) A pancreatic islet transcription factor and uses thereof
WO2004059000A3 (de) Hochdurchsatz-geeignetes screening-verfahren zur identifikation von wirkstoffen mittels co-kultivierung
AU2003223871A1 (en) Method for the production of mos transistors
AU2002344611A1 (en) Method of diagnosing type 2 diabetes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WD Withdrawal of designations after international publication

Free format text: DE

WWE Wipo information: entry into national phase

Ref document number: 2003250773

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2489151

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004518441

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20038155907

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 375358

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 2003762453

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200500125

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2003762453

Country of ref document: EP

REF Corresponds to

Ref document number: 10393421

Country of ref document: DE

Date of ref document: 20050609

Kind code of ref document: P

WWE Wipo information: entry into national phase

Ref document number: 10393421

Country of ref document: DE

WWW Wipo information: withdrawn in national office

Ref document number: 2003762453

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006094071

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10520386

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10520386

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: DE